Cellular Biomedicine Group to Present "Expedited Development of Cellular Medicine" at Hong Kong Biotech Horizons Conference

Cellular Biomedicine Group to Present "Expedited Development of Cellular
Medicine" at Hong Kong Biotech Horizons Conference

PALO ALTO, Calif., Nov. 19, 2013 (GLOBE NEWSWIRE) -- Cellular Biomedicine
Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new
treatments for degenerative and cancerous diseases, today announced that Wei
(William) Cao, Ph.D., B.M., Chief Executive Officer, will present at the Hong
Kong Biotech Horizons Conference on Thursday, November 21, 2013, at 11:15 a.m.
at the Charles K. Kao Auditorium, Hong Kong Science and Technology Park, Hong
Kong.

The theme of the two day conference is "Translational Medicine: Promising
Researches in Cancer Therapies and Diagnostics". Dr. Cao will present the
subject, "Expedited Development of Cellular Medicine – An Effective
Translational Medicine Model Involving USA, Hong Kong and Mainland China". A
copy of the presentation will be available to view on the Company website the
following day.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental stem
cell, progenitor cell, and immune cell projects are the result of research and
development by scientists and doctors fromChinaandthe United States. Our
flagship GMP facility, consisting of eight independent cell production lines,
is designed, certified and managed according to U.S. standards. To learn more
about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         sarah.kelly@cellbiomedgroup.com
 
Press spacebar to pause and continue. Press esc to stop.